BRIEF published on 10/28/2024 at 13:35, 24 days 3 hours ago EnVVeno Medical lance une étude préclinique pour la valve enVVe EnVVeno Medical Approbation De La FDA Traitement CVI Étude BPL Soupape EnVVe
PRESS RELEASE published on 10/28/2024 at 13:30, 24 days 3 hours ago enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R) enVVeno Medical Corporation successfully completes first wave of implants with updated delivery system for enVVe replacement venous valve, on track for U.S. pivotal trial in mid-2025 EnVVeno Medical Corporation Venous Disease Implants EnVVe Pivotal Trial
BRIEF published on 09/27/2024 at 03:23, 1 month 24 days ago EnVVeno Medical Corporation annonce le prix d'une offre publique de 15 millions de dollars EnVVeno Medical Offre Publique Maladie Veineuse Valve VenoValve Groupe Titan Partners
BRIEF published on 09/27/2024 at 03:23, 1 month 24 days ago EnVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering Public Offering EnVVeno Medical VenoValve Venous Disease Titan Partners Group
PRESS RELEASE published on 09/27/2024 at 03:18, 1 month 24 days ago enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering enVVeno Medical Corporation announces pricing of underwritten public offering for the treatment of venous disease. Offering led by Titan Partners Group. Expected gross proceeds of $15.0 million Public Offering Gross Proceeds EnVVeno Medical Corporation Venous Disease Titan Partners Group
BRIEF published on 09/26/2024 at 22:10, 1 month 24 days ago EnVVeno Medical Corporation Announces Proposed Public Offering SEC Filing Public Offering EnVVeno Medical VenoValve Venous Disease
BRIEF published on 09/26/2024 at 22:10, 1 month 24 days ago EnVVeno Medical Corporation annonce un projet d'offre publique d'achat EnVVeno Medical Dépôt Auprès De La SEC Maladie Veineuse Valve VenoValve Offre Publique De Vente
PRESS RELEASE published on 09/26/2024 at 22:05, 1 month 24 days ago enVVeno Medical Corporation Announces Proposed Public Offering enVVeno Medical Corp. proposes public stock offering through underwritten public offering for venous disease treatment products. Funding for R&D and corporate needs Medical Devices EnVVeno Medical Corporation Venous Disease Treatment Public Stock Offering R&D Funding
BRIEF published on 09/03/2024 at 15:05, 2 months 18 days ago EnVVeno Medical nomme Sandy Prietto au poste de vice-président du marketing Dispositifs Médicaux EnVVeno Medical Approbation De La FDA Valve VenoValve Sandy Prietto
BRIEF published on 09/03/2024 at 15:05, 2 months 18 days ago EnVVeno Medical Appoints Sandy Prietto as VP of Marketing Medical Devices FDA Approval EnVVeno Medical VenoValve Sandy Prietto
Published on 11/21/2024 at 16:30, 18 minutes ago The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Published on 11/21/2024 at 16:01, 47 minutes ago Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 48 minutes ago Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight
Published on 11/21/2024 at 16:00, 48 minutes ago Wiz Acquires Dazz to Revolutionize Cloud Security Remediation
Published on 11/21/2024 at 15:41, 1 hour 6 minutes ago Edison issues report on Murray Income Trust (MUT)
Published on 11/21/2024 at 15:24, 1 hour 24 minutes ago Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/21/2024 at 15:23, 1 hour 25 minutes ago Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Published on 11/21/2024 at 15:22, 1 hour 26 minutes ago Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc
Published on 11/21/2024 at 06:58, 9 hours 50 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 50 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 50 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 20 hours 41 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 21 hours 28 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
